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Abstract
Oncoproteomics is the study of proteins and their interactions in a cancer cell by proteomic
technologies. Proteomic research first came to the fore with the introduction of two-dimensional
gel electrophoresis. At the turn of the century, proteomics has been increasingly applied to cancer
research with the wide-spread introduction of mass spectrometry and proteinchip. There is an
intense interest in applying proteomics to foster an improved understanding of cancer
pathogenesis, develop new tumor biomarkers for diagnosis, and early detection using proteomic
portrait of samples. Oncoproteomics has the potential to revolutionize clinical practice, including
cancer diagnosis and screening based on proteomic platforms as a complement to histopathology,
individualized selection of therapeutic combinations that target the entire cancer-specific protein
network, real-time assessment of therapeutic efficacy and toxicity, and rational modulation of
therapy based on changes in the cancer protein network associated with prognosis and drug
resistance. Besides, oncoproteomics is also applied to the discovery of new therapeutic targets and
to the study of drug effects. In pace with the successful completion of the Human Genome Project,
the wave of proteomics has raised the curtain on the postgenome era. The study of
oncoproteomics provides mankind with a better understanding of neoplasia. In this article, the
discovery of cancer biomarkers in recent years is reviewed. The challenges ahead and perspectives
of oncoproteomics for biomarkers development are also addressed. With a wealth of information
that can be applied to a broad spectrum of biomarker research projects, this review serves as a
reference for biomarker researchers, scientists working in proteomics and bioinformatics,
oncologists, pharmaceutical scientists, biochemists, biologists, and chemists.
Background
More than 11 million people are diagnosed with cancer
every year. It is estimated that there will be 16 million new
cases every year by 2020. From a total of 58 million deaths
worldwide in 2005, cancer accounts for 7.6 million (or
13%) of the global mortality. Deaths from cancer in the
world are projected to continue rising, with an estimated
9 million people dying from cancer in 2015 and 11.4 mil-
lion dying in 2030.
As an important biological indicator of cancer status and
progression for the physiological state of the cell at a spe-
cific time, biomarkers represent powerful tools for moni-
toring the course of cancer and gauging the efficacy and
safety of novel therapeutic agents. They can have tremen-
dous therapeutic impact in clinical oncology, especially if
the biomarker is detected before clinical symptoms or
enable real-time monitoring of drug response. There is a
critical need for expedited development of biomarkers
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and their use to improve diagnosis and treatment for can-
cer. Malignant transformation involves alterations in pro-
tein expression with subsequent clonal proliferation of
the altered cells. These alterations can be monitored at the
protein level, both qualitatively and quantitatively. Pro-
tein signatures in cancer provide valuable information
that may be an aid to more effective diagnosis, prognosis,
and response to therapy.
The recent progress of proteomics has opened new ave-
nues for cancer-related biomarker discovery. Advances in
proteomics are contributing to the understanding of
pathophysiology of neoplasia, cancer diagnosis, and anti-
cancer drug discovery. With the advent of new and
improved proteomic technologies such as the develop-
ment of quantitative proteomic methods, high-resolu-
tion, high-speed, high-throughput, high-sensitivity mass
spectrometry (MS) and proteinchip, as well as advanced
bioinformatics for data handling and interpretation, it is
possible to discover biomarkers that are able to reliably
and accurately predict outcomes during cancer treatment
and management. Besides, the newer technologies pro-
vide higher analytical capabilities, employing automated
liquid handling systems, fractionation techniques and
bioinformatics tools for greater sensitivity and resolving
power, more robust and higher throughput sample
processing, and greater confidence in analytical results can
be obtained. Oncoproteomics offers cutting-edge capabil-
ities to accelerate the translation of basic discoveries into
daily clinical practice. Continued refinement of tech-
niques and methods to determine the abundance and sta-
tus of proteins holds great promise for the future study of
cancer and the development of cancer therapies [1,2].
Current tumor markers
Early diagnosis of cancer is difficult because of the lack of
specific symptoms in early disease and the limited under-
standing of etiology and oncogenesis. For example, blood
tumor markers for breast cancer such as cancer antigen
(CA) 15-3 are useless for early detection because of low
sensitivity. Therefore measurement of carcinoembryonic
antigen (CEA) and HER-2 in abnormal nipple discharge
has been approved for diagnosis of breast cancer in some
countries [3]. More than 98% of cervical cancer is related
to human papillomavirus (HPV) infection. The identifica-
tion and functional verification of host proteins associ-
ated with HPV E6 and E7 oncoproteins may provide
useful information for the understanding of cervical car-
cinogenesis and the development of cervical cancer-spe-
cific markers [4]. For hepatocellular carcinoma (HCC),
the common method of screening high risk patients by
alpha-fetoprotein (AFP) and ultrasonography has been
shown to result in earlier detection and consequently
more easily treatable tumors and longer survival. Of the
other tumor markers, the newer high sensitive des-
gamma-carboxy-prothrombin has been found to be use-
ful. In addition, the AFP fractions L3, P4/5, and the +II
band are highly specific for HCC. Among routinely
assayed tumor markers in the laboratory, CA-125 is more
sensitive for HCC than AFP but far less specific [5]. Cur-
rently available screening tests for ovarian cancer include
CA-125, transvaginal ultrasound, or a combination of
both. CA-125 has provided a useful serum tumor marker
for monitoring response to chemotherapy. A rapid fall in
CA-125 during chemotherapy predicts a favorable prog-
nosis and can be used to redistribute patients on multi-
armed randomized clinical trials. Prostate-specific antigen
(PSA) is the most important tumor marker in all solid
tumors, indispensable in the management of prostate
cancer [6]. However, most currently available screening
tests for cancers lack high sensitivity and specificity to be
useful in screening the general population, so the differen-
tiation between some benign and malignant tumors is
still a clinical challenge. The advent of oncoproteomics
has provided the hope of discovering novel biomarkers
for use in the screening, early diagnosis, and prediction of
response to therapy (Table 1).
Diagnostic biomarkers
Diagnostic oncoproteomics is the application of pro-
teomic techniques for the diagnosis of malignancies. The
early detection of cancer has a potential to dramatically
reduce mortality. The thermostable fractions of serum
samples from patients with ovarian, uterus, and breast
cancers, as well as samples from benign ovarian tumor
were analyzed using two-dimensional gel electrophoresis
(2-DE) combined with matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF)/TOF MS. Of
them, alpha-1-acid glycoprotein and clusterin were
expressly down-regulated in breast cancer, whereas tran-
sthyretin was decreased specifically in ovarian cancer.
Apolipoprotein A-I forms have decreased spot volumes,
while haptoglobin alpha1, in contrast, was elevated in
several tumors. Serum thermostable fraction may be rec-
ommended as a good tool for medium and small protein
investigation, in particular, by 2-DE [7].
Bladder cancer
Celis and co-workers have utilized 2-DE and MS analysis
to identify differential protein expression between blad-
der cancer and healthy tissue including squamous cell car-
cinomas versus normal urothelium, which has defined
some of the steps involved in the squamous differentia-
tion of the bladder transitional epithelium [8]. On the
other hand, making use of 2-DE and MS/MS, Sheng et al
recently discovered that fatty acid binding proteins,
annexin V, heat shock protein (Hsp) 27, and lactate dehy-
drogenase were associated with bladder cancer. They also
found altered expression of a group of proteins in bladder
cancer that have not been documented previously, includ-Molecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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ing annexin I, 15-hydroxyprostaglandin dehydrogenase,
galectin-1, lysophospholipase, and mitochondrial short-
chain enoyl-coenzyme A hydratase 1 precursor [9].
Breast cancer
Isotope-coded affinity tag tandem MS allows for qualita-
tive and quantitative analysis of paired protein samples.
Alpha2-HS-glycoprotein was under-expressed in nipple
aspirate fluid from tumor-bearing breasts, while lipophi-
lin B, beta-globin, hemopexin, and vitamin D-binding
protein precursor were over-expressed [10].
Colorectal cancer
Six proteins (ANXA3, BMP4, LCN2, SPARC, MMP7, and
MMP11) were found to be over-expressed in colorectal
tumoral tissues by using immunoblotting and tissue
microarray analysis. Two of them (LCN2 and MMP11)
were clearly over-expressed in late Dukes stages (B and C)
[11]. To identify proteins with colorectal cancer (CRC)-
specific regulation, comparative 2-DE of individual-
matched normal and neoplastic colorectal tissue speci-
mens was performed. Endocrine cell-expressed protein
secretagogin exhibited a marked down-regulation in CRC
tissues. This finding may represent the basis for the clini-
cal application of secretagogin as a biomarker for a dis-
tinct subgroup of CRCs [12].
Esophageal cancer
Using agarose 2-DE and agarose 2-D difference gel electro-
phoresis (DIGE), a number of proteins with altered
expression between primary esophageal cancer and adja-
cent non-cancer tissues have been identified. Among
them, periplakin was significantly down-regulated in
esophageal cancer, which was confirmed by immunoblot-
ting and immunohistochemistry. These results suggested
that periplakin could be a useful marker for the detection
of early esophageal cancer and the evaluation of tumor
progression [13,14].
Gastrointestinal stromal tumor
To investigate the molecular characteristics of gastrointes-
tinal stromal tumor (GIST) according to mutation type,
protein expression profiles in GIST were analyzed using 2-
DE and MALDI-TOF MS. Among the 15 proteins differ-
ently expressed according to the mutation status, over-
expression of 5 proteins (annexin V, high mobility group
protein 1, C13orf2, glutamate dehydrogenase 1, and
fibrinogen beta chain) and decreased expression of
RoXaN correlated with a higher tumor grade. These find-
ings suggested that differential protein expression could
be used as diagnostic biomarkers [15].
Glioma
Application of direct tissue MALDI-TOF MS to human
brain tumors identified protein patterns that distin-
guished primary gliomas from normal brain tissue and
one grade of gliomas from another, with high sensitivity
and specificity [16].
Hepatocellular carcinoma
Comparative proteomic analysis was used to search for
characteristic alterations in the sera of HCC patients who
had undergone curative radiofrequency ablation treat-
ment subjected to 2-DE, and the proteins were identified
by MS based on MALDI-TOF/TOF analysis and public
database searches. The statistical analysis suggested that 4
proteins decreased after treatment, including pro-apolipo-
protein, alpha2-HS glycoprotein, apolipoprotein A-IV
precursor, and PRO1708/PRO2044 (the carboxy terminal
fragment of albumin). Seven proteins were increased after
treatment, including leucine-rich alpha2-glycoprotein
and alpha1-antitrypsin. These data provided candidate
biomarkers for the development of diagnostic and thera-
peutic tools [17]. On the other hand, 2-D DIGE combined
with nano flow liquid chromatography (LC) tandem MS
was employed to investigate differentially expressed pro-
teins in HCC. 14-3-3γ protein was found to be up-regu-
Table 1: Comparison of proteomic biomarkers and current tumor markers
Cancer Proteomic biomarkers Current tumor markers
Sensitivity Specificity Reference Markers Sensitivity Specificity
Bladder 80% 90–97% [87] NMP22 31% 95%
Breast 93% 91% [88] CA 15-3 63% 80–88%
Colorectal 91% 93% [89] CEA 43% ****
Gastric 83% 95% [90] CEA 49% ****
Liver 94% 86% [91] AFP 50% 90%
Lung 87% 80% [92] Cyfra21-1 63% 94%
Ovarian 83% 94% [93] CA-125 57% ****
Pancreatic 78% 97% [94] CA 19-9 72% ****
Prostate 83% 97% [95] PSA 86% 20–34%Molecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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lated in HCC. 14-3-3 isoforms has been linked to
carcinogenesis because they are involved in various cellu-
lar processes such as cell cycle regulation, apoptosis, pro-
liferation, and differentiation [18]. Surface-enhanced
laser desorption/ionization (SELDI)-TOF MS was also
performed to identify differentially expressed proteins in
HCC serum using weak cation exchange proteinchips.
Protein characterization was performed by 2-DE separa-
tion and nano flow LC-MS/MS. Complement C3a was
detected as differentially expressed in patients with
chronic hepatitis C and hepatitis C virus-related HCC.
This result was further validated by PS20 chip immu-
noassay and Western blotting [19]. Besides, the use of pro-
teinchip technology in combination with tissue
microdissection has identified ferritin light subunit, ade-
nylate kinase 3 alpha-like 1, and biliverdin reductase B in
HCC [20].
Leukemia
DotScan microarray (a cluster of differentiation antibody
microarray) has been developed to enable an extensive
immunophenotype obtained for a suspension of leuko-
cytes in a single analysis. The antibody microarray is
printed as microscopic (10 nL) dots on a nitrocellulose
film on microscope slide. Cells are captured by the immo-
bilized antibodies and a dot pattern is recorded with an
optical array reader giving the immunophenotype of
leukemia. Procedures are developed to enable diagnosis
of myeloid leukemia by comparison of the dot pattern
obtained from an unknown blood sample with a library
of consensus patterns for common leukemia [21].
Lung cancer
Based on the assumption that proteins can emanate from
tumor to serum, Maciel et al investigated whether serum
proteins could discriminate lung adenocarcinoma
patients from healthy donors. Results of 2-DE/MALDI-
TOF showed 5 up-regulated proteins (immunoglobulin
lambda chain, transthyretin monomer, haptoglobin-alfa
2, and 2 isoforms of serum amyloid protein) and 1 down-
regulated protein (fragment of apolipoprotein A-I) in
lung adenocarcinoma patients [22].
Lymphoma
Fan et al making use of two-way hierarchical clustering
analysis of the protein expression profiles differentiated
reactive follicular hyperplasia, follicular lymphoma, and
Burkitt lymphoma, with 5 major clusters of differentially
expressed protein peaks for molecular classification of B
cell lymphoma subtypes. They identified histone H4 as a
potential differentially expressed protein marker that
seemed to distinguish grade 1 from grade 3 follicular lym-
phoma [23].
Nasopharyngeal carcinoma
Unfractionated whole sera of newly diagnosed Malaysian
Chinese patients with advanced nasopharyngeal carci-
noma were subjected to 2-DE and image analysis, cerulo-
plasmin showed higher expression. The enhanced
expression of ceruloplasmin in the patients' sera was con-
firmed by competitive enzyme-linked immunosorbent
assay (ELISA) [24].
Ovarian cancer
Identified by MALDI-TOF MS and validated by Western
blotting, haptoglobin precursor significantly up-regulated
while transferrin precursor significantly down-regulated
in grade 3 ovarian cancer patients. Changes in serum
expression of haptoglobin correlated with the change of
CA-125 levels before and after chemotherapy [25]. Of
great significance, the technique worked well on patients
with early stage disease, offering the prospect of earlier
diagnosis which would greatly enhance the chance of suc-
cessful treatment outcome. This has led to the develop-
ment of a commercial test, termed OvaCheck, for
diagnosis of ovarian cancer.
Pancreatic cancer
The survival rate of pancreatic cancer patients is the lowest
among those with common solid tumors, and early detec-
tion is one of the most feasible means of improving out-
comes. Proteomic analysis combining 2-DE and MS
successfully identified 154 potential serum markers for
pancreatic cancer. Of these, fibrinogen γ, a protein associ-
ated with the hypercoagulable state of pancreatic cancer,
discriminated cancer from normal sera. Fibrinogen γ was
subsequently confirmed to be over-expressed in pancre-
atic cancer sera by enzymatic analysis and tissue by immu-
nohistochemistry relative to normal pancreas, thus it is a
potential tumor marker in pancreatic cancer [26]. Besides,
a PowerBlot analysis with more than 900 well-character-
ized antibodies was performed with tissue specimens
from patients with chronic pancreatitis, pancreatic adeno-
carcinoma, and normal pancreas. A large number of pro-
teins are differentially expressed in the chronic
pancreatitis and pancreatic adenocarcinoma compared
with the normal pancreas. Among them, expression anal-
ysis of UHRF1, ATP7A, and aldehyde oxidase 1 in combi-
nation could potentially provide a useful additional
diagnostic tool for fine-needle aspirated or cytological
specimens obtained during endoscopic investigations
[27].
Prostate cancer
A promising prostate cancer biomarker identified by 2-DE
and MS is annexin I. Studies have already confirmed that
annexin I is under-expressed in a majority of early stage
prostate cancer. Other non-gel-based proteomic technolo-
gies that may have improved sensitivity as compared to 2-Molecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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DE have recently been developed, one of the examples is
the ProteomeLab PF 2-D (Beckman Coulter Inc, Fullerton,
CA, USA). The goal of most proteomic studies is to iden-
tify biomarkers that can be measured by ELISA or immu-
nohistochemistry. Improvements in proteomic
technology are changing this paradigm because there are
now efforts to develop proteomic technologies directly
into clinical diagnostic tests, an example of these technol-
ogies is SELDI-TOF MS. Using this technology combined
with pattern recognition based bioinformatics tool, dis-
criminatory spectrum proteomic profiles were generated
which could help discriminating men with prostate cancer
from those with benign prostate [28].
Renal cancer
It is possible to define specific protein patterns in the
serum of renal cancer. Several proteins have been identi-
fied by SELDI, including serum amyloid alpha [29].
Urothelial carcinoma
Using capillary electrophoresis-coupled MS to obtain
polypeptide patterns from urine samples of patients with
urothelial carcinoma and healthy volunteers, a prominent
polypeptide from the diagnostic pattern for urothelial car-
cinoma was identified as fibrinopeptide A (a known
biomarker of ovarian cancer and gastric cancer). Valida-
tion of a highly specific biomarker pattern for urothelial
carcinoma in a large group of patients with various uro-
logical disorders can be used in the diagnosis of other dis-
eases that are identified in urine samples or in other body
fluids [30].
Screening biomarkers for cancers
Population proteomics is an applied proteomics subdisci-
pline engaging in the investigation of human proteins
across and within populations to define and better under-
stand protein diversity. Population proteomics focuses on
interrogation of specific proteins from a large number of
individuals, utilizing top-down, targeted affinity MS
approaches to probe protein modifications. Deglycosyla-
tion, sequence truncations, side-chain residue modifica-
tions and other modifications have been reported for
myriad of proteins, yet little is known about their inci-
dence rate in the general population. Such information
can be gathered via population proteomic studies, and
would greatly aid the biomarker discovery efforts. Identi-
fication of novel protein modifications is also expected
from such large-scale population proteomic studies,
expanding the protein knowledge database. In regards to
tumor biomarkers, their validation via population pro-
teomic approaches is advantageous as MS detection is
used both in the discovery and validation process, which
is essential for the detection of structurally modified
tumor biomarkers [31].
For instance, screening of the head and neck carcinoma
patients with the proteomics-based autoantibody-medi-
ated identification of antigens technology yielded a set of
tumor-associated antigens. Expression of cytokeratin (CK)
8 correlated positively with malignancies of the head and
neck areas. CK8 is an attractive marker molecule for a dif-
ferentiated diagnosis between leukoplakia with head and
neck carcinomas, which possesses notedly improved spe-
cificity as compared with panCK and CK13 [32].
Biomarkers in cancer development
The action of regulatory circuits, cross-talk between path-
ways and the non-linear reaction kinetics of biochemical
processes complicate the understanding and prediction of
the outcome of intracellular signaling [33]. Like normal
cells, most cancer cells use multiple redundant intracellu-
lar signaling pathways to ensure the maintenance and via-
bility of functions critical to their survival. Thus, cellular
pathways that are integral to cell function, survival, prolif-
eration, and receptor expression are potential targets for
therapeutic intervention, with epidermal growth factor
receptor (EGFR) signaling pathway as one of the good
examples. Clinicians might recommend combinations of
molecularly targeted agents and other therapies on the
basis of an individual patient's proteomic profile [34].
Understanding the molecular basis of the biochemical
pathways involved in carcinogenesis can facilitate the
integration of diagnosis, anticancer drug discovery, and
therapy for cancer. The powerful -omic technologies have
enabled the identification of key biomarkers and signal-
ing molecules associated with cell growth, cell death, and
cellular metabolism. A realistic model of cellular regula-
tion based on current knowledge indicates that many
interacting networks operate at the epigenetic, transcrip-
tional, translational, and post-translational levels, with
feedback between the various levels. Protein-protein and
protein-DNA interactions help to define which genes may
be activated in a particular cell, and determine whether
external cues cause activation or repression. Proteomic
technologies will ultimately characterize information-
flow through the protein circuitry that interconnects the
extracellular microenvironment to the serum or plasma
macroenvironment through the intracellular signaling
systems and their control of gene transcription. The pur-
pose of differential and functional proteomics is to obtain
this information which will lead to improved understand-
ing of cellular pathways and their inter-relationships in
cells and living organisms. The nature of this information
can be a cause or a consequence of disease processes and
how patients respond to therapy [35]. New technologies,
such as proteomics using MS, high-density DNA or oligo-
nucleotide microarrays, and chromatin immunoprecipi-
tation provide new and exciting tools for deciphering the
pathways and proteins controlling gene expression. Anal-Molecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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ysis of these pathways offers new insight that aids targeted
drug development which promises to revolutionize clini-
cal practice [36].
For example, changes in protein expression levels revealed
a significantly enhanced glycolytic pathway (Warburg
effect), a decreased gluconeogenesis, a suppressed glu-
curonic acid pathway, and an impaired tricarboxylic acid
cycle in CRC using MALDI-TOF/TOF MS. Observed
changes in protein abundance were verified by 2-D DIGE.
These changes reveal an underlying mechanism of color-
ectal tumorigenesis in which the roles of impaired tricar-
boxylic acid cycle and Warburg effect may be critical [37].
On the other hand, the study of the human colon cancer
proteome represents a step toward to a better understand-
ing of the metabolomics of colon cancer at early stages
confined to the intestinal wall. A shift from beta-oxida-
tion, as the main source of energy, to anaerobic glycolysis
was observed owed to the alteration of nuclear- versus
mitochondrial-encoded proteins and other proteins
related to fatty acid and carbohydrate metabolism. Lower
capacity for Na(+) and K(+) cycling was found, and oper-
ativity of the apoptosis pathway (especially the mitochon-
drial one) was concluded [38]. It is suggested that CRC
may be prevented by changes in diet, and vegetable con-
sumption has been demonstrated to have a protective
effect. Until now, little is known about the effects of vege-
table consumption at the proteome level. Six proteins
were identified by MALDI-TOF MS, including myosin reg-
ulatory light chain 2, carbonic anhydrase I, high-mobility
group protein 1, pancreatitis-associated protein 3, glycer-
aldehyde-3-phosphate dehydrogenase, and ATP synthase
oligomycin sensitivity conferral protein. Alterations in the
levels of these proteins agreed with a role in the protection
against colon cancer. The observed altered protein levels
therefore provided support for the protective effects of
vegetables against CRC [39]. Another good example is the
Epstein-Barr virus (EBV) study, EBV-encoded latent mem-
brane protein 1 (LMP1) can activate NF-κB, activator pro-
tein-1, and Janus kinases/signal transducer and activation
of transcription factors pathways. Combining the novel
strategy of phosphoprotein enrichment with proteomic
technology to elucidate the signaling cascade activated by
LMP1, it was reported that LMP1 could increase the quan-
tity of total phosphoproteins. The other proteins, includ-
ing annexin A2, Hsp27, stathmin, annexin I, basic
transcription factor 3, and porin, were novel signaling
molecules or targets with no previously known function
in LMP1 signal transduction. The method used has
proven to be suitable for the identification of molecules
involved in various signaling pathways [40].
A comprehensive understanding of the metastatic path-
ways is crucial for the improvement of the limited thera-
peutic weapons currently at disposal. Some studies have
addressed this subject very recently, biochemical confir-
mation of cleavage of the potential substrates was per-
formed and the cleavage sites were identified by MALDI-
TOF. Using proteomics and metabolic profiling, sorbitol
(a component of an alternative glycolysis pathway) was
significantly elevated at 5.4-fold in renal cell carcinoma
patients as compared to the controls. This finding may be
used to influence the choice of optimal therapy [41].
Overall and Dean discovered and confirmed that CTGF,
galectin-1, death receptor-6, Hsp90alpha, procollagen C-
proteinase enhancer protein, chemokine fractalkine, and
cystatin C were novel MT1-matrix metalloproteinases
(MMP) or MMP-2 substrates. These sophisticated cellular
control functions highlight new intervention points in
multiple pathways to treat early stage cancer [42]. On the
other hand, analysis of 5 independent studies comprised
of greater than 1 × 106 genomic sequences and greater
than 1,000 proteins revealed that the cytoskeletal-associ-
ated protein alpha-actinin was increased at both the
mRNA and protein level in metastatic breast, prostate, and
skin cancer cells. Spatial analysis of alpha-actinin expres-
sion revealed that it was amplified 8-fold in the leading
pseudopodium compared to the cell body compartment
of migrating cells. These findings indicated that amplifica-
tion of alpha-actinin and its localization to the leading
pseudopodium were potential biomarkers of cancer pro-
gression to a more metastatic phenotype [43].
Biomarkers for targets in cancer therapy
Results from genomic and proteomic studies are eagerly
awaited for selecting patients, avoiding the use in non-tar-
geted situation and reducing the cost of treatments. One
of the major contributions proteomics has made to the
medical and pharmaceutical communities is the identifi-
cation of potential drug targets. Many cancers are charac-
terized by alternations in certain signaling pathways and
identification of the aberrant pathway in a particular
patient allows for targeted therapy to that specific path-
way. For example, epithelial ovarian cancer is often char-
acterized by activation of EGFR signaling pathway, and
targeted therapies including monoclonal antibodies, such
as cetuximab and small molecule inhibitors such as gefit-
inib are either in clinical use or under clinical trial for dif-
ferent stages of cancer. Similarly, the c-Kit and platelet-
derived growth factor receptor inhibitor, Imatinib, has
shown remarkable success in chronic myeloid leukemia
and GIST, cancers that are maintained by the activation of
these receptor tyrosine kinases.
Proteinchip has been employed to measure enzyme activ-
ity of secreted and membrane proteomes of cancer cell
lines, and are now being used to measure kinase activity
via specific detection of phosphoproteins [44]. It is
believed that phosphorylation of various proteins, such as
cyclin E, cyclin D, p27, IκB-α, and STAT1, allows them toMolecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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be ubiquitinated and marked for proteolysis by the pro-
teasome complex. On the other hand, phosphorylation of
other proteins, such as c-Fos and c-Jun, prevents their
ubiquitination. This further indicates a direct involvement
of the proteasome in cell proliferation and cell cycling
processes. The first selective proteasome inhibitor, borte-
zomib (Velcade), has been synthesized for recognizing the
potential of a proteasome inhibitor as a novel cancer ther-
apeutic, and found out the relationship between the pro-
teasome, NF-κB and multiple myeloma. Proteasomes are
large multi-subunit protease complexes that are localized
in the nucleus and cytosol which selectively degrade intra-
cellular proteins. They play a major role in the degrada-
tion of many proteins involved in cell cycling,
proliferation, and apoptosis. The ubiquitin-proteasome
pathway involves in the breakdown of short-lived abnor-
mal proteins which result from oxidative stress and muta-
tions that might otherwise disrupt normal cellular
homeostasis. The reactive oxygen species promote partial
unfolding of the proteins, exposing its hydrophobic
domains to proteolytic enzymes of 20S complex. Ubiqui-
tin-medicated pathway in cancer includes ubiquitin-med-
icated down-regulation of receptor tyrosine kinases in
cancer, control of the cell cycle by the ubiquitin system,
regulation of DNA repair by the ubiquitin system and its
implication in cancer. It has been shown that actively pro-
liferating cancer cells are more susceptible to the action of
proteasome inhibitors than non-cancerous cells. Consti-
tutively active NF-κB pathway is common in several solid
tumors and proteasome inhibitors block this activation
and make cancer cells more susceptible to radiation ther-
apy and chemotherapeutic agents.
Breast cancer
The monoclonal antibody inhibitor of HER-2, trastuzu-
mab (Herceptin), has been used successfully as mono-
therapy and in combination with chemotherapy in
women with HER-2 over-expressing metastatic breast can-
cer [45-48]. Besides, hormone receptors have been used as
reliable predictive factors for response to endocrine ther-
apy. Other biomarkers have been investigated to select
patients with tumors hormone receptors-positive but
unresponsive to endocrine therapy [3]. Proteomics-based
studies have also widened our knowledge of transforming
growth factor-β-dependent regulation of cell prolifera-
tion, apoptosis, DNA damage repair and transcription.
This leads to better understanding of the transforming
growth factor-β role in human breast tumorigenesis and
opens the avenue for the development of novel anticancer
treatments and drugs, with some of the drugs already
entering clinics [49].
Colorectal cancer
Bevacizumab receives European Union approval for the
first-line treatment of metastatic CRC in combination
with irinotecan- or 5-FU-based chemotherapy. Bevacizu-
mab prevents interaction of VEGF with VEGFR1 (FLT-1)
and VEGFR2 (KDR) on the surface of endothelial cells to
inhibit angiogenesis. Bevacizumab is used for the first-line
and second-line treatment of metastatic CRC. Besides,
cetuximab became the first EGFR-targeting monoclonal
antibody approved for use in metastatic CRC in 2004.
Cetuximab is an IgG1 monoclonal antibody that specially
targets the EGFR with high affinity and competitively
inhibits endogenous ligand binding. It binds exclusively
EGFR and its heterodimers, blocks receptor dimerisation,
tyrosine kinase phosphorylation, and signal transduction.
Cetuximab has shown good efficacy in combination with
irinotecan in CRC that had previously progressed on iri-
notecan-based therapy. Cetuximab plus irinotecan and
various schedule of 5-FU/FA have shown efficacy in a first-
line setting [50].
Hepatocellular carcinoma
By reverse transcriptase-polymerase chain reaction, a
1,741 bp cDNA encoding a protein that is differentially
expressed in HCC have been isolated. This novel protein
was identified by proteomic analysis and was designated
as Hcc-2, which is up-regulated in poor-differentiated
HCC but unchanged in well-differentiated HCC. This
work demonstrated that an integrated proteomic and
genomic approach could be a very powerful means of dis-
covering potential diagnostic and therapeutic protein tar-
gets for cancer therapy [51].
Prostate cancer
The identification of antigens expressed by prostate tissue
and/or prostate cancer that are recognized by T cells or
antibodies creates opportunities to develop novel immu-
notherapeutic approaches including tumor vaccines. Pro-
teins expressed in prostate cancer including PSA, prostatic
acid phosphatase, and prostate membrane antigen have
been used as immunologic targets for immunotherapy
[52].
Biomarkers for therapeutic response 
monitoring and prognosis
Prognostication and the variability of tumor responses to
radio-/chemo-therapeutic agents is a topic of major inter-
est in current cancer research. The advances in proteomic
research will lead to a plethora of new molecular markers,
which are likely to be correlated with disease activity, pro-
gression, and survival. Pharmacoproteomics, a novel dis-
cipline that investigates the protein expression in tumor
cells and the response to anticancer agents, evaluation of
radio-/chemo-therapy particularly for the characterization
of drug-resistance mechanisms, will be instrumental in
developing optimal anticancer regimens for patients.
Mechanisms mediating drug-resistance are multifaceted.
Rapid developments in proteomic technologies haveMolecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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made it possible to simultaneously identify multiple pro-
teins involved in drug refractory cancers. Advances in the
knowledge of dysregulation of key molecular pathways in
cancer cells have enabled techniques to be developed that
can profile tumor cells for their genetic background,
allowing selection of anticancer agents on an individual
basis. The next generation of anticancer treatments might
therefore be tailored according to the molecular altera-
tions identified in tumor cells of individual patients
[53,54].
Bladder cancer
At least 50% of patients with a history of bladder cancer
have recurrences, so rigorous surveillance is necessary. The
noninvasive point-of-care assay for elevated urinary
nuclear matrix protein NMP22 can increase the ability to
detect recurrent bladder cancer [55].
Breast cancer
The presence of progesterone receptor (PR) in estrogen
receptor (ER) positive breast cancer is associated with a
good prognosis, and indicates that tumors are likely to
respond to tamoxifen. However, ER+/PR- tumors respond
less well. Owing to the fact that current proteomic meth-
ods are hampered in the examination of most primary
human tumor samples by the extreme tissue heterogene-
ity, laser capture microdissection was used to isolate
tumor cells and developed a sample pooling strategy to
analyze small sample protein lysates. The differentially
displayed proteins included decreased cytochrome b5 and
transgelin, and more abundant CRABP-II, cyclophilin A,
neudesin, and hemoglobin in ER+/PR+ tumors versus
ER+/PR- providing a possible explanation for differential
susceptibility against tamoxifen as a result of deregulated
cytochrome b5-dependent metabolism [56]. Besides,
SELDI-TOF MS showed that a high level of cytosolic ubiq-
uitin and a low level of ferritin light chain were associated
with a good prognosis in breast cancer. Differential
expressions of the two proteins were further confirmed by
Western blotting analysis and immunohistochemistry
[57]. Furthermore, multidrug resistance is a major obsta-
cle to successful breast cancer treatment. Following 2-DE
and MALDI-TOF MS analysis, functional validation
showed that the elevated 14-3-3σ expression contributed
considerably to the observed drug resistance in MCF7/
AdVp3000 cells. Its altered expression in tumors might
cause clinical resistance to chemotherapy [58].
Hepatocellular carcinoma
Employing 2-DE and MS/MS, 3 chaperone members
(Hsp27, Hsp70, and glucose-regulated protein 78) were
found to be over-expressed in HCC tissues. Confirmed by
Western blotting and immunohistochemistry, no signifi-
cant association of Hsp70 with any pathologic features
was observed. The HCC proteome analysis revealed that
in response to the stressful cancerous microenvironment,
tumor cells strived to increase the expression of chaperone
proteins for cyto-protective function and to enhance
tumor growth and metastasis [59].
Leukemia
Using the comparative proteomic approach, several Hsps
known to complex Bcr-Abl were over-expressed in imat-
inib resistant chronic myelogenous leukemia cells, show-
ing a possible involvement of these proteins in the
mechanism of resistance. HnRNPs also resulted in being
up-regulated in imatinib resistant cells. These proteins
have been shown to be strongly and directly related to Bcr-
Abl activity [60].
Lymphoma
Pharmacogenetics and pharmacoproteomics have been
instrumental in developing optimal chemotherapeutic
regimens for patients with non-Hodgkin's lymphoma
[61]. Correlating the protein expression profiles by 2-DE
with clinical staging of B cell chronic lymphocytic leuke-
mia patients, Hsp27 was found to be over-expressed in
patients with shorter survival times. Down-regulation of
thioredoxin peroxidase 2 and protein disulfide isomerase
also correlated to decreased survival times. Identification
of these proteins is of particular prognosis value in B cell
chronic lymphocytic leukemia patients [62].
Nasopharyngeal carcinoma
Using SELDI-TOF MS analysis, Cho et al have identified
serum biomarkers (two isoforms of serum amyloid A pro-
tein) that were useful to monitor relapse of nasopharyn-
geal carcinoma. Monitoring the patients longitudinally
for serum amyloid A level both by proteinchip and immu-
noassay showed a dramatic increase, which correlated
with relapse and a drastic fall correlated with response to
salvage chemotherapy [63]. Using similar approach, 13
other serum biomarkers (including ITIH4 and PF4) that
are associated with active disease or chemotherapy
response in nasopharyngeal carcinoma patients were fur-
ther discovered [64,65].
Ovarian cancer
Analyzed by peptide fragment matching and MS/MS, cis-
platin caused notably increase expressions of some pro-
teins in ovarian cancer, including tropomyosin family,
actin family, triosephosphate isomerase family, and
Hsp60, while expressions of some proteins in the enolase
family decreased. Those proteins were involved in cellular
energy metabolism, transformation, apoptosis, and mor-
phologic maintenance suggested that alterations of the
physiological processes might be involved in antitumor
mechanism of cisplatin [66]. Besides, more than 30 serum
markers have been evaluated alone and in combination
with CA-125 by different investigators. Some of the mostMolecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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promising proteins include HE4, mesothelin, M-CSF,
osteopontin, kallikrein, and soluble EGF receptor. Serum
markers may improve the sensitivity of detecting recurrent
disease and facilitate earlier detection of ovarian cancer
[67].
Challenges
Identification of large numbers of proteins from complex
biological samples is a continuing challenge in the area of
quantitative proteomics. When coupled with 2-D-LC/
nano- electrospray ionization-MS, this method allows
enhanced protein identification when tested on samples
from prokaryotic and eukaryotic sources. The sample
complexity can be effectively reduced with corresponding
increases in protein identification using the multistep
method. This strategy represents a potentially powerful
technique for large-scale qualitative and quantitative pro-
teome research [68].
New challenges arise in large scale proteomic profiling
when dealing with complex biological mixtures such as
mammalian cell lysate. The approach of protein separa-
tion prior to the shotgun multidimensional protein iden-
tification technology was explored. Using the PF 2-D
ProteomeLab system, the mammalian cancer cell lysate
was fractionated and the distribution of molecular weight,
isoelectric point, and cellular localization of the eluted
proteins were analyzed. Sample complexity was reduced
by protein fractionation and the possibility of detecting
proteins with lower abundance in the complex protein
mixture was increased [69]. Another difficult task is to
identify protein from formalin-fixed paraffin-embedded
specimens. Recent research has successfully overcome this
bottleneck, which has significant implications for tandem
MS-based proteomics of vast repositories of archival pri-
mary tissue samples for disease-related discovery research
[70].
The biological variability among patient samples as well
as the huge dynamic range of biomarker concentrations is
also the current main challenge to deduce diagnostic pat-
terns that are unique to specific cancer states [71]. Speci-
men manipulations such as sample collection, pipetting,
and diluting contribute to pre-analytical variables. In
biomarker research, samples are usually collected from
multiple sites and randomly divided into discovery (train-
ing) sets and validation (testing) sets. Differences in sam-
ple collection, handling or storage, and profiling
techniques, may influence the protein profile obtained
from a given sample [72-74]. Wang et al introduced a sim-
ple "single-tube" preparation protocol appropriate for
small protein samples using the organic cosolvent, trif-
luoroethanol, to circumvent the loss of sample by facili-
tating both protein extraction and protein denaturation
without requiring a separate cleanup step [75]. Anyway,
issues regarding biological variation, pre-analytical varia-
bles and analytical variability must be tackled.
Although proteomics has proved its promise for biomar-
ker discovery, further work is still required to enhance the
performance and reproducibility of established proteomic
tools before they can be routinely used in clinical labora-
tory. It is becoming increasingly recognized that reproduc-
ibility and validation of tumor biomarkers should be
addressed carefully, as should their origin and identity. An
extremely important aspect of the Human Proteome
Organization is to provide standardization of techniques,
particularly once proteome analyses become routine use
in the clinical setting. A number of technical obstacles
remain before routine proteomic analysis can be achieved
in the clinic. However, the standardization of methodolo-
gies and dissemination of proteomic data into publicly
available databases is starting to overcome these hurdles.
Furthermore, the cost is also a precluding factor for the
widespread use of proteomics in clinical laboratory. Most
proteomic technologies use complex instrumentation,
critical computing power, and expensive consumables.
Another major challenge will be the integration of pro-
teomic with genomic and metabolomic data and their
functional interpretation in conjunction with clinical
results and epidemiology [76].
On the other hand, life sciences are rapidly changing from
disciplines that were dealing with relatively small datasets
to research areas bombarding with large and huge data
sets. When proteomic technology matures, we may even
see datasets with more than a million variables. Due to the
large numbers of variables, exhaustive search that would
guarantee finding the best subset cannot be implemented.
Because of these difficulties, many studies reported in the
literature pretty much neglect this step and apply more or
less arbitrary selection of features used to build classifica-
tion models. Usual approach is to find an ordered list of
features using simple univariate methods like ANOVA
and then use some of the features from the top of the list.
Such a univariate approach not only neglects correlations
between variables, but also results in removing from
important discriminatory information. Traditional uni-
variate approach, which has dominated life sciences for a
very long time, is no longer adequate. Different
approaches are necessary and multivariate analysis should
become a standard one.
Another limiting step in the biomarker pipeline is assay
development. If one can discover hundreds of candidates
at the tissue or blood level, the problem is going to be
assaying the hundreds of candidates in hundreds of sam-
ples. Although ELISA is the standard clinical assay for low-
abundant proteins, it is too expensive to implement on
large scale. Therefore, it is suggested to use the method ofMolecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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stable isotope standards and capture by anti-peptide anti-
bodies and multiple-reaction-monitoring MS. Some
researchers are investigating this method to develop mul-
tiplexed assays for several potential biomarkers [77].
Perspectives
Genomics offers the opportunity to examine gene expres-
sion or the variation in gene sequence, whereas proteom-
ics encompasses evaluation of protein expression,
activation, modification, degradation, and ambitiously
targets protein function. The human proteome, due to the
enormity of post-translational permutations that result in
large numbers of isoforms, is much more complex than
the genome and alterations in cancer which can occur in
ways that are not predictable by translational analysis
alone. Conceptually, proteomics bears the advantage of
incorporating both post-translational modifications
(PTMs) as well as host factors. This is thought to be impor-
tant in factors influencing survival such as chemo-resist-
ance. Proteomic approach avoids overlooking PTMs not
detected at gene level and the limited correlation between
transcript and protein levels. Phosphorylation is a
dynamic PTM that regulates the function of many pro-
teins, and is intimately involved in cellular signaling path-
ways. Using a proteomic approach, Nishio et al identified
marked differences in the phosphorylation status of spe-
cific nuclear proteins between drug sensitive and cis-
diamminedichloro-platinum (II)-resistant cell lines [78].
Tyrosination-detyrosination is another PTM of tubulin,
and Western blotting analysis has shown that tyrosinated
tubulin is increased in paclitaxel-resistant breast cancer
cells [79]. Histone proteins are subject to a range of PTMs
in living cells. Deciphering of the histone code is ham-
pered by the lack of analytical methods for monitoring the
combinatorial complexity of reversible multisite modifi-
cations of histones, including acetylation and methyla-
tion. Mass spectrometry-based quantitative proteomic
analysis of PTMs is a viable approach for functional anal-
ysis of candidate drugs, such as histone deacetylase inhib-
itors [80].
Since most novel therapeutic targets are proteins, pro-
teomic analysis potentially has a central role in patient
care. Understanding the molecular basis of tumor charac-
teristics will usher a new era of individualized cancer ther-
apy. Oncoproteomic analysis therefore represents a more
direct way of investigating malignancy at the individual
cancer patient level. Personalized management of cancer
means the prescription of specific therapeutics that best
suit for an individual patient and the type of tumor.
Oncoproteomics will play an important role in the devel-
opment of personalized cancer therapy. Molecular diag-
nostics influences cancer management in several ways that
aid personalization. Oncoproteomics for cancer staging
and personalization of therapy at the time of diagnosis
could improve patient care. Application of pharmacoge-
netics will reduce the adverse effects of anticancer drugs.
Cell/gene therapies, cancer vaccines, and RNA interfer-
ence will facilitate the development of personalized can-
cer therapy [81,82].
The discovery of new highly sensitive and specific biomar-
kers for early disease detection and risk stratification cou-
pled with the development of personalized therapies
holds the key to future treatment of cancer. It is becoming
clear that mapping the entire networks rather than indi-
vidual markers may be necessary for robust diagnostics
and tailoring of therapy. The emerging of oncoproteomics
offers great promise for unraveling the complex molecular
events of tumorigenesis, as well as those that control clin-
ically important tumor behaviors such as metastases,
invasion, and resistance to therapy. Functional imaging,
biosensors, and sophisticated computational biology are
having an unprecedented impact on the pharmaceutical
industry [83]. Advanced proteomic platforms such as
Orbitrap MS, Fourier transform ion cyclotron resonance
MS, and protein microarrays can generate a rapid and
high resolution portrait of the proteome  [84]. Emerging
novel nanotechnology strategies to amplify and harvest
tumor biomarkers in vitro or in vivo will greatly enhance
our ability to discover and characterize molecules for early
cancer detection, subclassification, and prognostic capa-
bility of current proteomic modalities [85]. New types of
proteomic technologies combined with advanced bioin-
formatics are currently being used to identify molecular
signatures of individual tumors based on protein path-
ways and signaling cascades. It is envisaged that analyzing
the cellular circuitry of ongoing molecular networks will
become a powerful clinical tool in cancer patient manage-
ment [86].
Unlike information gathered by classical methods, high-
throughput proteomic technologies can accurately inform
clinicians on patient response to adjuvant therapy or
those who will resist the effect of that therapy. Studies per-
formed in cancer with high-throughput techniques have
focused on tumor biology, prognosis, prediction of
response to a few agents, and early diagnosis. Biomarker
research has become a sign of the times, and the identified
biomarkers may be used for clinical diagnostic or prog-
nostic purposes. Biomarkers may also be used to help
devising an optimal therapeutic treatment plan for differ-
ent patient subsets and to monitor the effect of treatment.
In this way, protein markers may be used to accelerate the
speed and efficacy of clinical trials. Analysis of tumor-spe-
cific proteomic profiles permits better understanding of
neoplasia development and the discovery of novel molec-
ular targets for cancer therapy. Oncoproteomics plays an
important role in cancer research and will have a signifi-
cant impact on the development of future diagnostic andMolecular Cancer 2007, 6:25 http://www.molecular-cancer.com/content/6/1/25
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therapeutic products. In years to come, a serum or urine
test for every phase of cancer may drive clinical decision
making, supplementing or replacing currently existing
invasive techniques.
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